Supreme Court Expands Immunity for Big Pharma

The U.S. Supreme Court gave pharmaceutical companies another gift today, largely shielding the generic industry from lawsuits for the design of their drugs.  This is the second Supreme Court decision giving the generic drug industry immunity. In 2011, the Court decided generic makers cannot be held responsible for failing to warn about a drug’s side-effects, saying the generic maker is only making a “copy” of the brand drug and must follow the brand drug’s label. 

The case Mutual Pharmaceutical v. Bartlett is about Karen Bartlett, a woman who permanently suffers from Stevens-Johnson syndrome after taking the generic drug sulindac for shoulder pain.  The disease left Karen nearly blind and caused over 60% of her skin to burn off.  She spent months in a coma and a year being tube fed. She is permanently disfigured and will need care for the rest of her life.

Two lower courts in New Hampshire ruled sulindac is unreasonably dangerous and awarded Karen $21 million.  The Supreme Court’s decision nullifies those rulings.

Members of Congress (Senator Leahy and Senator Landrieu) have sent letters to the Food and Drug Administration, calling on the agency to address generic drug accountability.  Public Citizen also filed a citizen petition asking the FDA to address the Mensing decision.  AAJ filed comments in support of the petition. 

Hundreds of cases have been dismissed because of the Supreme Court’s Pliva v. Mensing decision.  Public Citizen issued a new report today highlighting how many potential hazards are not discovered until years after drugs have been on the market and the risk this poses to patients.  

Be sure to tell your member of Congress to support legisation to protect your medicine cabinet.